Home
Bafna Pharmaceuticals Ltd Share Price History
Bafna Pharmaceuticals Ltd
NSE : 17 Apr, 2025
74.84-0.0 (-0.0%)
Prev Close
74.9
Open Price
77.6
Bid Price (QTY)
-
Offer Price (QTY)
-
Volume
146
Today's High / Low
77.6 / 73.1
52 WK High / Low
113.0 / 69.0
Market Price of Bafna Pharmaceuticals Ltd
1M
1Y
3Y
5Y
Monitoring Bafna Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.
History Market Price
| Date | Price | Open | High | Low |
|---|
Returns Comparison
1W
1M
3M
6M
1Y
3Y
5Y
10Y
Growth Parameters
| Parameter |  2017 |
|---|---|
| Sales (Cr.) | NaN |
| Sales YoY Gr. | - |
| Adj EPS | 0 |
| YoY Gr. | - |
| Net Profit (Cr.) | -19 |
| BVPS | 20.73 |
Key Financial Parameters
| Parameter | 2012 |
|---|---|
| Return on Capital Emp. % | 9.07 |
| Op. Profit Mgn % | 15.33 |
| Net Profit Mgn % | 1.46 |
| Debt to Equity % | 1.32 |
Latest Shareholding
Promoters Holdings Over Time
About Bafna Pharmaceuticals Ltd
- Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products.
- The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
- Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
- During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.
Popular Search
FAQs for Bafna Pharmaceuticals Ltd Share Price History
What are the key events that typically impact Bafna Pharmaceuticals Ltd's share price history?
Key events that impact Bafna Pharmaceuticals Ltd’s share price history include quarterly earnings releases, product launches, leadership changes, economic policies, and geopolitical developments.
How do stock splits affect Bafna Pharmaceuticals Ltd's share price history?
Stock splits reduce the nominal price of Bafna Pharmaceuticals Ltd's shares by increasing the number of outstanding shares, which typically makes the stock more accessible to a broader range of investors. Although the total market value of the company remains unchanged after the split, the split can affect investor perception and liquidity, potentially influencing the share price in the longer term.
How do dividends impact the share price history of Bafna Pharmaceuticals Ltd?
Dividends can influence Bafna Pharmaceuticals Ltd's share price history by typically causing a temporary dip on the ex-dividend date, as the stock price often adjusts to reflect the dividend payout. Over time, the impact of dividends on the share price may be offset by the company's overall financial performance and market conditions.
How do corporate announcements affect Bafna Pharmaceuticals Ltd’s share price history?
Corporate announcements such as mergers, acquisitions, or strategic shifts can lead to significant price changes. Any optimistic development news on Bafna Pharmaceuticals Ltd generally boosts the company’s share price, whereas negative news can lead to a decline in share price.
How can I use technical analysis to understand Bafna Pharmaceuticals Ltd’s share price history?
To understand Bafna Pharmaceuticals Ltd’s share price history using technical analysis, examine charts for patterns such as trends, support, and resistance levels, and apply indicators like moving averages or Relative Strength Index (RSI) to gauge potential future movements. Analyze historical data to identify recurring trends and signals that might suggest how the share price could behave under similar conditions.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
